Loading stock data…
INDV
$37.66+0.88 (+2.39%)
Market ClosedLast close May 1
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Indivior Pharmaceuticals, Inc. in the Healthcare sector is trading at $37.66. The stock is currently near its 52-week high of $40.02, remaining 28.5% above its 200-day moving average. Technical signals show overbought RSI of 78 and bullish MACD crossover, explaining why INDV maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 78) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$37.66
Potential Downside
113.9%
Whystock Fair Value$-5.22
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Can...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.05B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
20.27
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.21
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-104.04%
Volume
Today's trading volume
3.16M
Recent News
Is It Too Late To Consider Indivior Pharmaceuticals (INDV) After A 214% One-Year Surge?
Investors may be wondering whether Indivior Pharmaceuticals at US$37.66 still offers value after its strong run, or if most of the opportunity is already reflected in the price. The stock has posted returns of 13.3% over the last 7 days, 22.9% over the last 30 days, 5.4% year to date, and 214.4% over the last year. These moves naturally raise questions about both upside potential and changing risk. Recent attention on Indivior Pharmaceuticals has focused on its position within the US...
Here's Why Momentum in Indivior Pharmaceuticals Inc. (INDV) Should Keep going
Indivior Pharmaceuticals Inc. (INDV) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
AGIO Beats on Q1 Earnings & Sales, Stock Up 13% on New Drug Momentum
Agios shares jump 13% as Q1 revenues surge 138% on Aqvesme launch and Pyrukynd growth, while pipeline advances and SCD filing plans take shape.
VKTX Q1 Earnings Miss on Higher Phase 3 Development Costs
Viking Therapeutics posts a wider Q1 loss as R&D spend jumps on Phase III obesity drug work, while it advances VK2735 studies and preps oral late-stage study.
Indivior Q1 Earnings Call Highlights
Indivior (NASDAQ:INDV) reported first-quarter 2026 results showing strong growth in U.S. SUBLOCADE and sharply higher profitability, while also outlining changes to its pipeline and detailing capital allocation actions taken during the quarter. Q1 results driven by SUBLOCADE growth and operating le